12 news items
Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2
ALKS
22 Aug 24
pathways that project widely throughout the brain.1 Targeting the orexin system may address excessive
Cantor Fitzgerald Reiterates Overweight on Alkermes, Maintains $48 Price Target
ALKS
25 Jul 24
Cantor Fitzgerald analyst Charles Duncan reiterates Alkermes (NASDAQ:ALKS) with a Overweight and maintains $48 price target.
JP Morgan Maintains Neutral on Alkermes, Raises Price Target to $32
ALKS
25 Jul 24
JP Morgan analyst Jessica Fye maintains Alkermes (NASDAQ:ALKS) with a Neutral and raises the price target from $31 to $32.
Baird Maintains Outperform on Alkermes, Raises Price Target to $38
ALKS
25 Jul 24
Baird analyst Joel Beatty maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises the price target from $37 to $38.
HC Wainwright & Co. Maintains Neutral on Alkermes, Raises Price Target to $37
ALKS
25 Jul 24
HC Wainwright & Co. analyst Douglas Tsao maintains Alkermes (NASDAQ:ALKS) with a Neutral and raises the price target from $35 to $37.
ek8wzwxk4k jfnxcfemuucygnxxhvrzl9ossy2atdkr1r739oretil
ALGM
ALKS
ALLR
24 Jul 24
an Overweight to Neutral and lowered its price target from $494 to $404.
Alphabet Inc
ib8iiu6scdvdyw70el qr1zp1d
ALKS
AVTR
CHKP
24 Jul 24
target from $41 to $51.
QuidelOrtho Corporation
s1vmplt9l clpu8jgiz
ALKS
15 Jul 24
The 12-month price targets, analyzed by analysts, offer insights with an average target of $36.33, a high estimate of $48.00, and a low
iunzup622uvtsmn0xal7qxp492pnncq3rqeq2iczxhb1shiyukqj
ALKS
15 Jul 24
JP Morgan analyst Jessica Fye maintains Alkermes (NASDAQ:ALKS) with a Neutral and lowers the price target from $32 to $31.
ey027v
ALKS
17 Jun 24
0
0
The 12-month price targets, analyzed by analysts, offer insights
p094e0owv1czrovxadr1ywulcdjev0veky46yc74o4nk75
ALKS
17 Jun 24
TD Cowen analyst Joseph Thome initiates coverage on Alkermes (NASDAQ:ALKS) with a Buy rating and announces Price Target of $34.
qdontp6saustxt fnzr
ALKS
4 Jun 24
HC Wainwright & Co. analyst Douglas Tsao reiterates Alkermes (NASDAQ:ALKS) with a Neutral and maintains $35 price target.
- Prev
- 1
- Next